Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis

T. Yanagisawa, F. Quhal, T. Kawada, K. Bekku, E. Laukhtina, P. Rajwa, MV. Deimling, M. Chlosta, B. Pradere, PI. Karakiewicz, K. Mori, T. Kimura, M. Schmidinger, SF. Shariat

. 2023 ; 15 (15) : 1309-1322. [pub] 20230911

Language English Country England, Great Britain

Document type Meta-Analysis, Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23016092

Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016092
003      
CZ-PrNML
005      
20231026110445.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/imt-2023-0039 $2 doi
035    __
$a (PubMed)37694583
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan $1 https://orcid.org/0000000274100712
245    10
$a Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis / $c T. Yanagisawa, F. Quhal, T. Kawada, K. Bekku, E. Laukhtina, P. Rajwa, MV. Deimling, M. Chlosta, B. Pradere, PI. Karakiewicz, K. Mori, T. Kimura, M. Schmidinger, SF. Shariat
520    9_
$a Aim: To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Results: Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. Conclusion: OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x terapie $7 D002292
650    12
$a nádory ledvin $x terapie $7 D007680
650    _2
$a imunoterapie $7 D007167
650    _2
$a sunitinib $7 D000077210
650    _2
$a inhibitory kontrolních bodů $7 D000082082
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, 32253, Saudi Arabia $1 https://orcid.org/0000000281636953
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8530, Japan $1 https://orcid.org/0000000283699712
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8530, Japan $1 https://orcid.org/0000000300021592
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119435, Russia $1 https://orcid.org/0000000289530272
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, Medical University of Silesia, Zabrze, 41-800, Poland $1 https://orcid.org/0000000340736584
700    1_
$a Deimling, Markus von $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany $1 https://orcid.org/0000000299543413
700    1_
$a Chlosta, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Clinic of Urology & Urological Oncology, Jagiellonian University, Krakow, 30-688, Poland
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, 31130, France $1 https://orcid.org/0000000277688558
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics & Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, H2X 0A9, Canada
700    1_
$a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan $1 https://orcid.org/0000000261476569
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan $1 https://orcid.org/0000000256731553
700    1_
$a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, 19328, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, 15006, Czech Republic $u Department of Urology, Weill Cornell Medical College, NY 10021, USA $u Karl Landsteiner Institute of Urology & Andrology, Vienna, 1090, Austria $1 https://orcid.org/0000000266276179
773    0_
$w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 15, č. 15 (2023), s. 1309-1322
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37694583 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110439 $b ABA008
999    __
$a ok $b bmc $g 1999922 $s 1202454
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 15 $d 1309-1322 $e 20230911 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options